Investment in Production Facilities to Ensure High Quality and Stable Supply
First written in FY2017. 4 of 8 entries say "Restated". Latest entry: FY2023-Q3.
0 other companies' latest entry also says "Restated".
- FY2023-Q3RestatedAnnual report
「To meet growing demand for these core products, the new tablet building constructed at the Toyama Plant to manufacture hormone tablets is scheduled to begin full-scale operations in 2023. We will expand hormone-tablet production capacity, contribute further to improving women's well-being and fulfil our responsibility to ensure a stable supply.」
The company continues to report that the new tablet building constructed at the Toyama Plant will begin full-scale operations in 2023, expand production capacity and contribute to a stable supply. - FY2023-Q2RestatedAnnual report
「To meet growing demand for these core products, the new tablet building constructed at the Toyama Plant to manufacture hormone tablets is scheduled to begin full-scale operations in 2023. We will expand hormone-tablet production capacity, contribute further to improving women's well-being and fulfil our responsibility to ensure a stable supply.」
The company continues its policy of investing in facilities at the Toyama Plant to expand production capacity and ensure a stable supply in response to growing demand for core products. - FY2022RestatedAnnual report
「Total capital expenditure during the consolidated fiscal year was ¥3,392 million.」
The company continues capital expenditure aimed at ensuring high quality and a stable supply, and discloses total capital expenditure of ¥3,392 million. - FY2021AdvancedAnnual report
「Total capital expenditure during the consolidated fiscal year was ¥3,392 million.」
The company continues capital expenditure aimed at ensuring high quality and a stable supply, and discloses capital expenditure of ¥3,392 million for the fiscal year. - FY2020AdvancedAnnual report
「Total capital expenditure during the consolidated fiscal year was ¥2,965 million.」
The company continues capital expenditure aimed at ensuring high quality and a stable supply, with capital expenditure increasing from ¥1,965 million in the previous fiscal year to ¥2,965 million. - FY2019AdvancedAnnual report
「The group continues to invest in expanding production facilities capable of providing a stable supply of high-quality pharmaceuticals. Total capital expenditure during the consolidated fiscal year was ¥1,965 million.」
The company continues capital expenditure aimed at ensuring high quality and a stable supply, and discloses capital expenditure of ¥1,965 million for the fiscal year. - FY2018RestatedAnnual report
「The group continues to invest in expanding production facilities capable of providing a stable supply of high-quality pharmaceuticals. Total capital expenditure during the consolidated fiscal year was ¥1,109 million.」
The company continues capital expenditure aimed at ensuring high quality and a stable supply, and discloses capital expenditure of ¥1,109 million for the fiscal year. - FY2017First statedAnnual report
「The group continues to invest in expanding production facilities capable of providing a stable supply of high-quality pharmaceuticals. Total capital expenditure during the consolidated fiscal year was ¥1,605 million.」
The company continues capital expenditure aimed at ensuring high quality and a stable supply, and reports the investment amount for the fiscal year.